BioSpace News Archive

The Gilbert Family Foundation, a private nonprofit established by Jennifer and Dan Gilbert to accelerate a cure for neurofibromatosis type 1, announced funding of a new $5.4 million clinical study.

CalciMedica Inc. (“CalciMedica” or the “Company”), the CRAC channel company, today announced the results from CARDEA, a Phase 2 trial of its lead drug candidate Auxora™ in patients with severe COVID-19 pneumonia.

Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the expansion of the Company’s executive management team.

Adaptive Phage Therapeutics, Inc. today announced the appointment of Jesse L. Goodman, MD, MPH, to the company’s Board of Directors.

Luminopia today announced the publication of positive Phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One

Twist Bioscience Corporation today announced that it has started shipping its synthetic RNA reference controls for the SARS-CoV-2 AY.1 and AY.2

Neurogene Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for NGN-101. NGN-101

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will present at the 2021 Cantor Global Healthcare Conference

Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, announced a pilot study was recently published in Annals of Reviews and Research highlighting the ability of its Ultimate Brain Nutrients™ (UBN™) ACTIVATE™ to naturally increase key brain activity by as much as 46%.

Rafael Holdings, Inc., a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals, Inc., announced the appointment of Patrick Fabbio as Chief Financial Officer.